eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2009
vol. 13
 
Share:
Share:
abstract:
Review paper

Possibilities for adjuvant treatment in colon cancer

Rafał Stec
,
Lubomir Bodnar
,
Cezary Szczylik

Współczesna Onkologia (2009) vol. 13; 2 (53-60)
Online publish date: 2009/05/04
View full text Get citation
 
Each year almost a million patients receive a diagnosis of colorectal cancer and it is the cause of death of half a million patients. Approximately 13 000 new cases are diagnosed each year in Poland. Almost 230 000 patients are candidates for adjuvant chemotherapy following surgery yearly. The age of first diagnosis of CRC is 40 years, but rapidly increases from 50 years. CRC was reported to be the most common cancer in Poland in patients who were ł 65 years (62% in male and 66% in female of all cases of CRC). The proportions of deaths ł 65 years are 70% in males and 77% in females. In adjuvant therapy of colon cancer are used: LF (leucovorin and 5-Fu), capecitabine and FOLFOX (oxaliplatin and 5-Fu and leucovorin). In stage II of the TNM scale adjuvant chemotherapy can be used for patients with high-risk factors after individual analysis and based on only the LF schedule. Based on clinical trials, in stage III of the TNM scale FOLFOX should be used for optimal adjuvant chemotherapy of colon cancer. In case of intolerance of the FOLFOX schedule, capecitabine or the LF schedule can be considered.
keywords:

colon cancer, adjuvant therapy, chemotherapy, capecitabine, FOLFOX

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.